Guidewire Announces 2019.1 Release of P&C Insurance Industry Platform to Accelerate Insurer Growth
7.5.2019 23:55:00 EEST | Business Wire | Press release
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the 2019.1 release of Guidewire InsurancePlatform™. This latest release supports insurers’ imperatives to optimize operations, be more digital, use data in new ways, and innovate quickly. Underlying these business drivers is a general theme to simplify and de-risk insurers’ IT environments.
“Insurers today are driving towards more continuous delivery of technology enabled capabilities to their internal and external stakeholders. Increased release cadence of vended core systems like Guidewire InsurancePlatform, will help insurers address increasing time to market demands and improved upgrade experience,” said Martina Conlon, executive vice president, Research and Consulting and practice leader for property/casualty at Novarica.
Guidewire InsurancePlatform has been designed to power the P&C insurance business, in support of the following key insurer imperatives:
Use data in new ways: InsurancePlatform helps insurers drive smart decisions across the insurance lifecycle by leveraging scientific techniques and delivering actionable insights at the time key decisions are being made:
- New innovations in Guidewire Predictive Analytics™ make it easier to import and operationalize models built with third-party software, prevent overfitting of certain variables, allow for gradual adoption of model recommendation, and monitor overall impact on claims, pricing, and submissions.
Improve digital engagement: To meet rising digital expectations, InsurancePlatform 2019.1 helps insurers increase digital engagement by digitizing every interaction and delivering a satisfying, consumer grade, omnichannel experience.
- Provides more streamlined quoting experiences for customers, agents, brokers, and customer service representatives (CSRs) through enhanced quote flow navigation that enables users to move back and forth in quote flows while maintaining the integrity of the data submitted, thus improving the speed and efficiency of the quoting process.
- Innovative error handling in Guidewire ProducerEngage™ and Guidewire ServiceRepEngage™ notifies agents, brokers, and CSRs of data entry errors and qualification issues as they occur, allowing them to address issues right away to save time and avoid working on quotes that cannot be bound. The alerts fall into three categories: error messages, warnings, and underwriting approval alerts.
Innovate quickly: To empower insurers to respond to changing competition and new entrants, InsurancePlatform enables innovation while reducing complexity of integrations with promising insurtechs as well as established players.
- Insurers can choose from 100 Guidewire validated third party solution integrations currently available for download in the Guidewire Marketplace.
- Guidewire PartnerConnect™ Solution partners added since the October 2018 release include: ACI Worldwide, Advanced Remarketing Services, Franco Signor, Mirror Technologies, Omadi, Ontellus, TruePic, and Zipwhip.
- In the past four months, 7 Solution Partners have signed up to use the new Guidewire DevConnect™ developer environment to create plug and play Ready for Guidewire add-ons for ClaimCenter: Advanced Remarketing Services, Livegenic, Mirror Technologies, Omadi, Ontellus, TruePic and WeGoLook.
Simplify IT complexity: InsurancePlatform reduces IT complexity and minimizes the operational burden with key infrastructure improvements to InsuranceSuite.
- The Policy Migration Tool reduces the cost and risk associated with legacy policy migration into Guidewire PolicyCenter™ by providing a supported tool that simplifies the process.
- The InsuranceSuite Behavior Testing Framework promotes better collaboration between business and IT by enabling business analysts to create InsuranceSuite test scenarios in everyday language.
“InsurancePlatform releases remain focused on simplifying the technology that supports insurers, while improving digital engagement across the customer lifecycle, enabling insurers to achieve their business imperatives,” said Ayan Sarkar, principal, InsurancePlatform, Guidewire. “2019.1 unveils exciting new products, features, and tools in support of these objectives.”
Guidewire InsuranceSuite™ has been positioned as a Leader in Gartner’s Magic Quadrant for P&C Core Platforms, North America1. Guidewire Software has also been positioned as a Leader in Gartner’s Magic Quadrant for Non-Life-Insurance Platforms, Europe2.
Note that not all products are available in every geography. Guidewire customers can get more information from their Account Executive.
1 Gartner, Magic Quadrant for P&C Core Platforms, North America, Jeff Haner, October 9, 2018
2 Gartner, Magic Quadrant for Non-Life Insurance Platforms, Europe, Sham Gill, 26 November 2018
Gartner Disclaimer
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
About Guidewire Software
Guidewire delivers the industry platform that Property and Casualty (P&C) insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and partner ecosystem to enable our customers to run, differentiate, and grow their business. We are privileged to serve more than 350 companies in 32 countries. For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
NOTE: All products mentioned in this announcement are Guidewire products. For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190507006111/en/
Contact information
Diana Stott
Director, Communications
Guidewire Software
+1
650-356-4941
dstott@guidewire.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
